Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children
- 1 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 59 (8), 1049-1061
- https://doi.org/10.1007/s40262-020-00877-z
Abstract
Background Busulfan therapeutic drug monitoring (TDM) is necessary to better achieve the target exposure in children before hematopoietic stem cell transplantation (HSCT). However, TDM-based dosing may be challenging if intra-individual pharmacokinetic variability (also denoted inter-occasion variability [IOV]) occurs during therapy. Objectives The objectives of this study were to describe and quantify busulfan IOV in children, and to investigate its potential determinants. Methods We performed a new analysis of published data from children who received intravenous busulfan over 4 days before HSCT. We calculated individual pharmacokinetic parameters on each day of therapy using a published population pharmacokinetic model of busulfan and analyzed their changes. Population estimation of IOV was also performed with non-linear mixed effects (NLME) modeling. Potential predictors of significant decrease in busulfan clearance (CL) were assessed by using machine learning approaches. Results IOV could be assessed in 136 children. Between day (D) 1 and D2, most patients (80%) experienced a decrease in busulfan CL, with a median change of - 7.9%. However, both large decreases (minimum, - 48.5%) and increases in CL (maximum, + 44%) were observed. Over D1-D3 of therapy, mean CL significantly decreased (- 15%), with a decrease of >= 20% in 22% of patients. Some patients also showed unstable CL from day to day. NLME modeling of IOV provided a coefficient of variation of 10.6% and 13.1% for volume of distribution (V-d) and CL, respectively. Some determinants of significant decreases in busulfan CL were identified, but predictive performance of the models was limited. Conclusions Significant busulfan intra-individual variability may occur in children who receive a HSCT and is hardly predictable. The main risk is busulfan overexposure. Performing TDM repeatedly over therapy appears to be the best way to accurately estimate busulfan exposure and perform precision dosing.This publication has 37 references indexed in Scilit:
- Variation in Prescribing Patterns and Therapeutic Drug Monitoring of Intravenous Busulfan in Pediatric Hematopoietic Cell Transplant RecipientsThe Journal of Clinical Pharmacology, 2013
- Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation PatientsClinical Pharmacokinetics, 2012
- Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older ChildrenTherapeutic Drug Monitoring, 2012
- Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in ChildrenClinical Cancer Research, 2011
- Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipientsBritish Journal of Clinical Pharmacology, 2008
- Cyclophosphamide following Targeted Oral Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, Liver Toxicity, and MortalityTransplantation and Cellular Therapy, 2007
- I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipientsBone Marrow Transplantation, 2004
- The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantationBone Marrow Transplantation, 2003
- Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimensBone Marrow Transplantation, 2001
- Bayesian Analysis in Expert SystemsStatistical Science, 1993